Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 16957507)

1.

Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions.

Fischer B, Reimer J, Firestone M, Kalousek K, Rehm J, Heathcote J.

Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1039-42. Review.

PMID:
16957507
2.

Young brains on cannabis: It's time to clear the smoke.

Porath-Waller AJ, Notarandrea R, Vaccarino FJ.

Clin Pharmacol Ther. 2015 Jun;97(6):551-2. doi: 10.1002/cpt.111. Epub 2015 May 2.

PMID:
25778103
3.

[Cannabis - abuse and consequences.]

Wøien VA, Horwitz H, Høgberg LC, Askaa B, Jürgens G.

Ugeskr Laeger. 2015 Feb 2;177(6). pii: V04140228. Danish.

PMID:
25650575
4.

Are users' most recent drug purchases representative?

Bond B, Caulkins JP, Scott N, Kilmer B, Dietze P.

Drug Alcohol Depend. 2014 Sep 1;142:133-8. doi: 10.1016/j.drugalcdep.2014.06.016. Epub 2014 Jun 23.

PMID:
25008105
5.

Commentary on Vink et al. (2014): The polygenic basis of drug use-does context matter?

Lynskey M, Agrawal A.

Addiction. 2014 Jul;109(7):1152-3. doi: 10.1111/add.12583. No abstract available.

PMID:
24903292
6.
7.

Significance of cannabis use to dental practice.

Maloney WJ.

Todays FDA. 2012 Jan-Feb;24(1):40-1, 43-5, 47.

PMID:
22474927
8.

Significance of cannabis use to dental practice.

Maloney WJ.

J Mich Dent Assoc. 2011 Nov;93(11):44-8.

PMID:
22235566
9.

[Managing the use of cannabis in a young population in primary care].

Madoz-Gúrpide A, Ochoa Mangado E.

Aten Primaria. 2011 Jun;43(6):319-24. doi: 10.1016/j.aprim.2010.10.002. Epub 2011 Feb 20. Spanish.

10.

Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies.

Zanini B, Covolo L, Donato F, Lanzini A.

Clin Ther. 2010 Dec;32(13):2139-59. doi: 10.1016/S0149-2918(11)00021-X.

PMID:
21316533
11.

[Short-term treatment of Hepatitis C in heroin-dependent patients].

Kristensen Ø, Sundøy A, Skeie K, Vederhus JK, Øye I, Opsal A, Rysstad O, Gallefoss F.

Tidsskr Nor Laegeforen. 2009 Aug 27;129(16):1639-42. doi: 10.4045/tidsskr.09.33690. Norwegian.

12.

[The relationship between emotional distress, cognitive performance and health - related quality of life in patients with hepatitis C prior to antiviral treatment].

Rothenhäusler HB, Scherr M, Putz-Bankuti C, Kapper A, Stepan A, Baranyi A, Haas-Krammer A, Haas B, Stauber R.

Fortschr Neurol Psychiatr. 2009 Aug;77(8):457-63. doi: 10.1055/s-0028-1109574. Epub 2009 Aug 12. German.

PMID:
19676008
13.

Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.

Vicknasingam B, Narayanan S, Navaratnam V.

Drug Alcohol Rev. 2009 Jul;28(4):447-54. doi: 10.1111/j.1465-3362.2009.00087.x.

PMID:
19594801
14.

Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.

Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ.

Liver Int. 2009 Aug;29(7):1051-5. doi: 10.1111/j.1478-3231.2008.01958.x.

PMID:
19580634
15.

Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review.

Zanini B, Lanzini A.

Antivir Ther. 2009;14(4):467-79. Review.

PMID:
19578232
16.

[Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].

Guillem E, Pelissolo A, Vorspan F, Bouchez-Arbabzadeh S, Lépine JP.

Encephale. 2009 Jun;35(3):226-33. doi: 10.1016/j.encep.2008.03.010. Epub 2008 Aug 19. French.

PMID:
19540408
17.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.

Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006.

PMID:
19485429
18.

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.

Brown NA.

Expert Opin Investig Drugs. 2009 Jun;18(6):709-25. doi: 10.1517/13543780902854194 . Review.

PMID:
19426125
19.

High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.

Gazdik F, Gazdikova K, Laktis K, Okruhlica L, Fejdiova K, Danis D, Pijak MR, Wsolova L, Kajaba I, Kratky A.

Bratisl Lek Listy. 2009;110(2):77-84.

PMID:
19408838
20.

New developments in the antiviral treatment of hepatitis C.

de Bruijne J, Weegink CJ, Jansen PL, Reesink HW.

Vox Sang. 2009 Jul;97(1):1-12. doi: 10.1111/j.1423-0410.2009.01187.x. Epub 2009 Apr 20. Review.

PMID:
19392783
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk